Albireo Pharma, Inc. (ALBO)

EDISON, N.J.--(BUSINESS WIRE)--Albireo Energy, a leading independent building controls and energy services provider and Huron Capital portfolio company, has been Certified™ by Great Place To Work® for the eighth year in a row. This award is based on what current employees say about their experience working at Albireo Energy. In 2025, 81% of employees said that Albireo Energy was a Great Place To Work – 24 points higher than the average U.S. company. “This recognition belongs to our employees,”.

EDISON, N.J.--(BUSINESS WIRE)--Albireo Energy, a leading independent building controls and energy services provider and a Huron Capital portfolio company, today announced the appointment of Brad Freeman as Senior Vice President of Mergers and Acquisitions (M&A). Freeman will drive Albireo Energy's M&A pipeline, identifying strong partner companies, directing disciplined due diligence with Huron Capital, and overseeing the negotiation, closing, and integration of new acquisitions. “The A.

PHOENIX--(BUSINESS WIRE)--Albireo Energy, a leading independent provider of building automation and energy services, today announced the continued growth of its Arizona Division and the appointment of Carla Miller as Vice President and General Manager, Arizona. Albireo Energy entered the Arizona market through its acquisition of Control Engineering, a respected provider of building automation and energy solutions serving the region for decades. Building on that strong foundation, Albireo Energy.

EDISON, N.J.--(BUSINESS WIRE)--Albireo Energy, a leading independent building controls and energy services provider and a Huron Capital portfolio company, today announced the launch of Private Cloud Services (PCS) — a secure, fully managed cloud service designed to host and protect Building Automation System (BAS) and Energy Power Management Systems (EPMS) data without the capital expense, complexity, or risk of traditional on-premise servers. PCS separates operational technology (OT) from core.

EDISON, N.J.--(BUSINESS WIRE)-- #BAS--Albireo Energy, a leading independent building controls and energy services provider, and Huron Capital portfolio company, today announced the launch of Critical Alarm Messenger (CALM), an IoT-enabled, 24x7 notification and escalation service to alert building owners and their teams of issues with their most critical building systems. CALM integrates into pre-existing building automation systems (BAS) to collect and store historical data from all designated critic.

EDISON, N.J.--(BUSINESS WIRE)-- #BuildingSystemsPerformance--Albireo Energy, a leading independent building controls and energy services provider and Huron Capital portfolio company, revealed its new brand positioning and identity in line with its focus on creating intelligent, high-performance buildings. “The new Albireo Energy brand represents our commitment to service innovation, excellence in project management, and unleashing our team of experts to help customers achieve maximum control over their buildings,” said Larr.

Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

NEW YORK , Jan. 30, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law 305 Broadway, 7th Floor  New York, NY 10007 (212) 682-3025  (888) 593-4771 stockinfo@weisslawllp.com Evoqua Water Technologies Corp. (NYSE: AQUA) Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Evoqua Water Technologies Corp. (NYSE: AQUA) in connection with the proposed acquisition of AQUA by Xylem Inc. ("Xylem").

Albireo Pharma, Inc. has entered into an agreement to get acquired by Ipsen. Bylvay is already approved for PFIC. Nevertheless, the stellar drug is poised to gain additional labels for Alagille syndrome and biliary atresia.

The market is moving higher, and these small companies are helping.

Albireo Pharma, Inc. (NASDAQ:ALBO ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Hans Vitzthum - Managing Director, LifeSci Advisors Ron Cooper - President and Chief Executive Officer Jan Musin - Chief Scientific Officer, Head of R&D Pamela Stephenson - Chief Commercial Officer Simon Harford - Chief Financial Officer Conference Call Participants Miriam Nolan - Jefferies Brian Skorney - Baird Ritu Baral - Cowen Seamus Fernandez - Guggenheim Tim Lugo - William Blair Andreas Argyrides - Wedbush Securities Thomas Yip - H. C. Wainwright Operator Good afternoon.

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS)

Conference call and webcast to be held at 4:30 pm ET Conference call and webcast to be held at 4:30 pm ET

Sales for Bylvay's first approved indication is increasing. The company recently posted superb data for an orphan disease known as Alagille Syndrome.

Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.